Filing Flows

Filing Flows › 8-K events › Pfizer

Pfizer: departure or appointment of directors and officers

Form 8-K filed Nov 3, 2026 · items 5.02

CFO changesPfizer Appoints Cecile Guegan as Chief Financial Officer

What the filing says

On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Pfizer at a glance

Latest quarterQ3 2026
Revenue$16.6B
Revenue Y/Y-0.4%
Operating margin20.4%
IndustryPharmaceutical Preparations

Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%. The chart follows the revenue to costs, profit and cash.

Pfizer: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent cfo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.